Click for best price
AdenoAssociated Virus AAV VectorBased Gene Therapy Market Size, Share 2023
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus (AAV) Vector-Based Gene Therapy. This report contains market size and forecasts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in global, including the following market information:
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Single-stranded AAV (ssAAV) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy include BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Percentages, by Type, 2022 (%)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Percentages, by Application, 2022 (%)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, market overview.
Chapter 2: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size in revenue.
Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Overall Market Size
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size: 2022 VS 2030
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players in Global Market
3.2 Top Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies Ranked by Revenue
3.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Companies
3.4 Top 3 and Top 5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players in Global Market
3.6.1 List of Global Tier 1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Markets, 2022 & 2030
4.1.2 Single-stranded AAV (ssAAV)
4.1.3 Self-complementary AAV (scAAV)
4.2 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue & Forecasts
4.2.1 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2023
4.2.2 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2024-2030
4.2.3 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2022 & 2030
5.1.2 Hemophilia
5.1.3 Ophthalmology
5.1.4 Lysosomal Storage Disorders
5.1.5 Neurological Disorders
5.1.6 Others
5.2 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue & Forecasts
5.2.1 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2023
5.2.2 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2024-2030
5.2.3 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2022 & 2030
6.2 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue & Forecasts
6.2.1 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2023
6.2.2 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2024-2030
6.2.3 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.3.2 US Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.3.3 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.3.4 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.4.2 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.3 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.4 U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.5 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.6 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.7 Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.8 Benelux Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.5.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.3 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.4 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.5 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.6 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.6.2 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.6.3 Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.7.2 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7.4 Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7.5 UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
7 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies Profiles
7.1 BioMarin Pharmaceutical
7.1.1 BioMarin Pharmaceutical Company Summary
7.1.2 BioMarin Pharmaceutical Business Overview
7.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.1.5 BioMarin Pharmaceutical Key News & Latest Developments
7.2 Sangamo Therapeutics
7.2.1 Sangamo Therapeutics Company Summary
7.2.2 Sangamo Therapeutics Business Overview
7.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.2.5 Sangamo Therapeutics Key News & Latest Developments
7.3 Amicus Therapeutics
7.3.1 Amicus Therapeutics Company Summary
7.3.2 Amicus Therapeutics Business Overview
7.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.3.5 Amicus Therapeutics Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 NightstaRx
7.6.1 NightstaRx Company Summary
7.6.2 NightstaRx Business Overview
7.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.6.5 NightstaRx Key News & Latest Developments
7.7 MeiraGTx
7.7.1 MeiraGTx Company Summary
7.7.2 MeiraGTx Business Overview
7.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.7.5 MeiraGTx Key News & Latest Developments
7.8 Sarepta Therapeutics
7.8.1 Sarepta Therapeutics Company Summary
7.8.2 Sarepta Therapeutics Business Overview
7.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.8.5 Sarepta Therapeutics Key News & Latest Developments
7.9 Neurocrine Biosciences
7.9.1 Neurocrine Biosciences Company Summary
7.9.2 Neurocrine Biosciences Business Overview
7.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.9.5 Neurocrine Biosciences Key News & Latest Developments
7.10 Voyager Therapeutics
7.10.1 Voyager Therapeutics Company Summary
7.10.2 Voyager Therapeutics Business Overview
7.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.10.5 Voyager Therapeutics Key News & Latest Developments
7.11 Asklepios Biopharmaceutical
7.11.1 Asklepios Biopharmaceutical Company Summary
7.11.2 Asklepios Biopharmaceutical Business Overview
7.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.11.5 Asklepios Biopharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Opportunities & Trends in Global Market
Table 2. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers in Global Market
Table 3. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints in Global Market
Table 4. Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Global Market
Table 5. Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Type
Table 9. List of Global Tier 1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2024-2030
Table 30. BioMarin Pharmaceutical Company Summary
Table 31. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 32. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. BioMarin Pharmaceutical Key News & Latest Developments
Table 34. Sangamo Therapeutics Company Summary
Table 35. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 36. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. Sangamo Therapeutics Key News & Latest Developments
Table 38. Amicus Therapeutics Company Summary
Table 39. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 40. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Amicus Therapeutics Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 44. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Roche Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 48. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. NightstaRx Company Summary
Table 51. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 52. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. NightstaRx Key News & Latest Developments
Table 54. MeiraGTx Company Summary
Table 55. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 56. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. MeiraGTx Key News & Latest Developments
Table 58. Sarepta Therapeutics Company Summary
Table 59. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 60. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. Sarepta Therapeutics Key News & Latest Developments
Table 62. Neurocrine Biosciences Company Summary
Table 63. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 64. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. Neurocrine Biosciences Key News & Latest Developments
Table 66. Voyager Therapeutics Company Summary
Table 67. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 68. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. Voyager Therapeutics Key News & Latest Developments
Table 70. Asklepios Biopharmaceutical Company Summary
Table 71. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offerings
Table 72. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Asklepios Biopharmaceutical Key News & Latest Developments
List of Figures
Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type in 2022
Figure 2. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application in 2022
Figure 3. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 8. By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 16. US Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 20. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 21. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 28. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 32. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 34. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
Figure 37. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 41. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
